While these studies suggest that TRAIL can promote atherogenesis and vascular disease, serum concentrations in patients with coronary artery disease (CAD) have demonstrated lower TRAIL levels inversely associated with the severity of CAD, and especially lower levels in patients with acute coronary syndromes, suggesting a protective role in cardiovascular diseases [44], [52]. The gene discussed is TNFSF10; the disease is acute coronary syndrome.